Funding for this research was provided by:
Sydäntutkimussäätiö
Paolo foundation
State Research Funding
University of Turku (UTU) including Turku University Central Hospital
Article History
Received: 18 December 2021
Accepted: 18 March 2022
First Online: 16 April 2022
Declarations
:
: Miss Salmivalli reports personal grant from Finnish foundation for Cardiovascular Research. Dr Kytö reports grants from Paolo foundation, State Research funding (VTR) and Finnish Foundation for Cardiovascular Research. Dr Boström reports grants from Finnish cancer Foundation, State Research Funding (VTR) and Prodound inc outside the submitted work, as well as consulting fees to Faron inc and honoria for presentations for Janssen, Astra-Zeneca. Dr Ettala has nothing to disclose.
: Due to the retrospective study design, informed consent was waived, and the participants were not contacted.
: This study was approved by the National Institute for Health and Welfare of Finland (permission no.: THL/2245/5.05.00/2019) and Statistics Finland (TK-53-484-20). The legal basis for processing personal data was public interest and scientific research (EU General Data Protection Regulation 2016/679, Article 6(1)(e) and Article 9(2)(j); Data Protection Act, Sections 4 and 6).